[go: up one dir, main page]

WO2008029237A3 - Combination therapies for rheumatoid arthritis - Google Patents

Combination therapies for rheumatoid arthritis Download PDF

Info

Publication number
WO2008029237A3
WO2008029237A3 PCT/IB2007/002468 IB2007002468W WO2008029237A3 WO 2008029237 A3 WO2008029237 A3 WO 2008029237A3 IB 2007002468 W IB2007002468 W IB 2007002468W WO 2008029237 A3 WO2008029237 A3 WO 2008029237A3
Authority
WO
WIPO (PCT)
Prior art keywords
rheumatoid arthritis
pharmaceutically acceptable
acceptable salt
combination therapies
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/002468
Other languages
French (fr)
Other versions
WO2008029237A2 (en
Inventor
Paul Steven Changelian
Samuel Hyman Zwillich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of WO2008029237A2 publication Critical patent/WO2008029237A2/en
Publication of WO2008029237A3 publication Critical patent/WO2008029237A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

This disclosure relates to pharmaceutical combination therapies for the treatment or prevention of arthritis, such as rheumatoid arthritis, in a human comprising a Janus Kinase inhibitor or a pharmaceutically acceptable salt thereof and at least one anti-arthritic agent or a pharmaceutically acceptable salt thereof. This disclosure also relates to certain methods for treating or preventing arthritis, such as rheumatoid arthritis, in a human comprising co-administering to a human a Janus Kinase inhibitor or a pharmaceutically acceptable salt thereof and at least one anti-arthritic agent or a pharmaceutically acceptable salt thereof.
PCT/IB2007/002468 2006-09-05 2007-08-24 Combination therapies for rheumatoid arthritis Ceased WO2008029237A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84270406P 2006-09-05 2006-09-05
US60/842,704 2006-09-05

Publications (2)

Publication Number Publication Date
WO2008029237A2 WO2008029237A2 (en) 2008-03-13
WO2008029237A3 true WO2008029237A3 (en) 2008-05-15

Family

ID=39047038

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/002468 Ceased WO2008029237A2 (en) 2006-09-05 2007-08-24 Combination therapies for rheumatoid arthritis

Country Status (4)

Country Link
JP (1) JP2008069149A (en)
AR (1) AR062658A1 (en)
TW (1) TW200823216A (en)
WO (1) WO2008029237A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010239396B2 (en) * 2009-04-20 2016-06-23 Auspex Pharmaceuticals, Llc Piperidine inhibitors of Janus Kinase 3
TWI466885B (en) 2009-07-31 2015-01-01 Japan Tobacco Inc Nitrogen-containing spiro compound and its medical use
AR079984A1 (en) 2010-01-12 2012-03-07 Hoffmann La Roche TRICYCLIC HETEROCICLIC COMPOUNDS, COMPOSITIONS AND ITS USE IN THE TREATMENT OF DISEASES MEDIATED BY THE INHIBITION OF JAK1
WO2011097087A1 (en) * 2010-02-05 2011-08-11 Pfizer Inc. Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors
CN102875555A (en) * 2012-09-27 2013-01-16 同济大学 Synthetic method of JAK (janus kinase) inhibitor Tofacitinib
CN103819474A (en) * 2013-11-04 2014-05-28 湖南华腾制药有限公司 Preparation method of tofacitinib
MX362290B (en) * 2013-12-09 2019-01-10 Unichem Lab Ltd An improved process for the preparation of (3r,4r)-(1-benzyl-4-me thylpiperidin-3-yl)-methylamine.
AU2016208906B2 (en) * 2015-01-20 2018-07-12 Wuxi Fortune Pharmaceutical Co., Ltd JAK inhibitor
CN105237463B (en) * 2015-10-09 2017-10-10 刘卫国 Preparation methods of one kind (3R, 4R) (base of 1 benzyl, 4 methyl piperidine 3) methylamine L bis- to toluoyltartrates
CN106146517B (en) * 2016-06-20 2018-08-28 山东大学 A kind of synthetic method of citric acid tropsch imatinib
CN107602569A (en) * 2017-10-23 2018-01-19 上海博悦生物科技有限公司 A kind of new pyrrole simultaneously [2,3 d] pyrimidine compound and its preparation method and use
CN114835631B (en) * 2021-02-01 2024-02-13 重庆恩联生物科技有限公司 Preparation method of cis-1-benzyl-4-methyl-3-methylamino-piperidine dihydrochloride

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042246A2 (en) * 1999-12-10 2001-06-14 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
WO2005051393A1 (en) * 2003-11-25 2005-06-09 Pfizer Products Inc. Method of treatment of atherosclerosis
EP1686130A1 (en) * 2000-06-26 2006-08-02 Pfizer Products Incorporated Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001042246A2 (en) * 1999-12-10 2001-06-14 Pfizer Products Inc. PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS
EP1686130A1 (en) * 2000-06-26 2006-08-02 Pfizer Products Incorporated Pyrrolo[2,3-d]pyrimidine compounds as immunosuppressive agents
WO2005051393A1 (en) * 2003-11-25 2005-06-09 Pfizer Products Inc. Method of treatment of atherosclerosis

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "comparison of 6 CP-690550 doses vs placebo, each combined with methotrexate, for the treatment of rheumatoid arthritis", 18 December 2006 (2006-12-18), XP002469625, Retrieved from the Internet <URL:http://clinicaltrials.gov/show/NCT00413660> [retrieved on 20080218] *
ANONYMOUS: "extension study of stage 1 subjects of study A3921009 for the prevention of acute rejection in kidney transplant patient", CLINICALTRIALS.GOV, 6 December 2005 (2005-12-06), XP002469626, Retrieved from the Internet <URL:http://clinicaltrials.gov/show/NCT00263328> *
BORIE DOMINIC C ET AL: "Combined use of the JAK3 inhibitor CP-690,550 with mycophenolate mofetil to prevent kidney allograft rejection in nonhuman primates", TRANSPLANTATION (HAGERSTOWN), vol. 80, no. 12, December 2005 (2005-12-01), pages 1756 - 1764, XP009096259, ISSN: 0041-1337 *
CETKOVIC-CVRLJE M ET AL: "Therapeutic potential of Janus kinase 3 (JAK3) inhibitors.", CURRENT PHARMACEUTICAL DESIGN 2004, vol. 10, no. 15, 2004, pages 1767 - 1784, XP009096151, ISSN: 1381-6128 *
DOAN TANYA ET AL: "Rheumatoid arthritis: An overview of new and emerging therapies", JOURNAL OF CLINICAL PHARMACOLOGY, vol. 45, no. 7, July 2005 (2005-07-01), pages 751 - 762, XP009096292, ISSN: 0091-2700 *
GOLDBLUM R: "Therapy of rheumatoid arthritis with mycophenolate mofetil", CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 1993 ITALY, vol. 11, no. SUPPL. 8, 1993, pages S117 - S119, XP009096173, ISSN: 0392-856X *
WALKER J G ET AL: "Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment", ANNALS OF THE RHEUMATIC DISEASES, vol. 65, no. 12, 7 June 2006 (2006-06-07), online, pages 1558 - 1564, XP009096143, ISSN: 0003-4967 *

Also Published As

Publication number Publication date
TW200823216A (en) 2008-06-01
JP2008069149A (en) 2008-03-27
AR062658A1 (en) 2008-11-26
WO2008029237A2 (en) 2008-03-13

Similar Documents

Publication Publication Date Title
WO2008029237A3 (en) Combination therapies for rheumatoid arthritis
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
WO2007087068A3 (en) Inhibitors of tyrosine kinases and uses thereof
WO2008139271A3 (en) A synergistic pharmaceutical combination for the treatment of cancer
WO2004105737A3 (en) Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
WO2007146426A3 (en) Nanoshells for drug delivery
CL2007002261A1 (en) COMPOUNDS DERIVED FROM IMIDAZO [1,2-B] PIRIDAZINA, QUINASA INHIBITORS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OR PREVENTION OF CANCER.
WO2005023179A3 (en) Combination methods of treating cancer
AU2005339139A8 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
IL221795B (en) Use of a pharmaceutical composition of methylnaltrexone, or a salt thereof, in the preparation of a medicament for treating the side effects of opioid treatment
WO2007084424A3 (en) Treatment of substance abuse
WO2006113498A3 (en) 2-amino-quinaz0lin-5-ones as hsp90 inhibitors useful in treating proliferation diseases
WO2006116148A3 (en) (7-arlysubstituted 2, 3-dihydr0-1-benz0furan-2-yl) alkylamines in the treatment&#39; of substance abuse
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
EP2030615A3 (en) Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
WO2007092469A3 (en) Combination of organic compounds
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
WO2007120485A3 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
WO2009035634A3 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors
PL368971A1 (en) Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
WO2007022408A3 (en) Combination methods of saha and targretin for treating cancer
EP2012807A4 (en) Pharmaceutical composition of enterosorbent and prebiotics, dosage forms, and the method for prevention and treatment of gastrointestinal disorders
WO2003015797A8 (en) Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07789673

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07789673

Country of ref document: EP

Kind code of ref document: A2